Targeting HOTAIRM1 Ameliorates Glioblastoma by Disrupting Mitochondrial Oxidative Phosphorylation and Serine Metabolism
Overview
Affiliations
Serine hydroxymethyltransferase 2 (SHMT2), which catalyzes the conversion of serine to glycine and one-carbon transfer reactions in mitochondria, is significantly upregulated in glioblastoma (GBM). However, the mechanism by which the stability of gene expression is maintained to drive GBM tumorigenesis has not been clarified. Herein, through microarray screening, we identified that HOXA Transcript Antisense RNA, Myeloid-Specific 1 (HOTAIRM1) modulates the SHMT2 level in various GBM cell lines. Serine catabolism and mitochondrial oxidative phosphorylation activities were decreased by HOTAIRM1 inhibition. Mechanistically, according to our mass spectrometry and eCLIP-seq results, HOTAIRM1 can bind to PTBP1 and IGF2BP2. Furthermore, HOTAIRM1 maintains the stability of by promoting the recognition of an mA site and the interaction of PTBP1/IGF2BP2 with mRNA. The stability of HOTAIRM1 can also be enhanced and results in positive feedback regulation to support the progression of GBM. Thus, targeting HOTAIRM1 could be a promising metabolic therapy for GBM.
Ma S, Hu Y, Xu W, Xiong W, Xu X, Hou Y Heliyon. 2024; 10(17):e37364.
PMID: 39296104 PMC: 11409114. DOI: 10.1016/j.heliyon.2024.e37364.
Mi J, Wang Y, He S, Qin X, Li Z, Zhang T Neoplasia. 2024; 56:101034.
PMID: 39128424 PMC: 11367117. DOI: 10.1016/j.neo.2024.101034.
Insights into the role of RNA mA modification in the metabolic process and related diseases.
Hu H, Li Z, Xie X, Liao Q, Hu Y, Gong C Genes Dis. 2024; 11(4):101011.
PMID: 38560499 PMC: 10978549. DOI: 10.1016/j.gendis.2023.04.038.
IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis.
Dhamdhere M, Gowda C, Singh V, Liu Z, Carruthers N, Grant C Oncogene. 2023; 42(19):1558-1571.
PMID: 36973517 PMC: 10547097. DOI: 10.1038/s41388-023-02671-0.
Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment.
Tan S, Yang Y, Yang W, Han Y, Huang L, Yang R J Exp Clin Cancer Res. 2023; 42(1):59.
PMID: 36899389 PMC: 9999652. DOI: 10.1186/s13046-023-02634-z.